Bortezomib as a potential treatment for prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Advanced prostate cancer often progresses to an androgen-independent form, necessitating improved therapeutic strategies.
• The proteasome is crucial for intracellular regulation and cancer cell survival, making it a viable therapeutic target.
• Prostate cancer cells exhibit dependency on proteasome function for critical survival mechanisms.

Purpose of the Study:

• To evaluate the safety and tolerability of bortezomib in patients with advanced prostate cancer.
• To investigate the correlation between bortezomib dosage, proteasome inhibition, and therapeutic response.
• To explore the potential of proteasome inhibition as a treatment for androgen-independent prostate cancer.

Main Methods:

• A Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) of once-weekly bortezomib.
• The study included a significant number of patients with androgen-independent prostate cancer.
• Measurements included proteasome inhibition levels, serum prostate-specific antigen (PSA) modulation, and serum interleukin-6 (IL-6) levels.

Main Results:

• The MTD for once-weekly bortezomib was established at 1.6 mg/m(2).
• A dose-dependent correlation was observed between bortezomib administration, proteasome inhibition, and a positive modulation of serum PSA.
• Evidence of down-regulation of serum IL-6, a downstream nuclear factor kappaB effector, was noted.

Conclusions:

• Bortezomib is a potential therapeutic agent for advanced prostate cancer, particularly the androgen-independent form.
• Preclinical data and Phase I trial results support further investigation of bortezomib.
• Combination therapies involving bortezomib with radiation or chemotherapy warrant additional research for androgen-independent prostate cancer.